Abaxis (NASDAQ: ABAX) and Zeltiq Aesthetics (NASDAQ:ZLTQ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
97.7% of Abaxis shares are owned by institutional investors. 4.3% of Abaxis shares are owned by company insiders. Comparatively, 15.6% of Zeltiq Aesthetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Abaxis and Zeltiq Aesthetics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Abaxis pays an annual dividend of $0.64 per share and has a dividend yield of 1.0%. Zeltiq Aesthetics does not pay a dividend. Abaxis pays out 59.3% of its earnings in the form of a dividend.
This is a breakdown of recent recommendations and price targets for Abaxis and Zeltiq Aesthetics, as reported by MarketBeat.com.
||Strong Buy Ratings
Abaxis currently has a consensus target price of $54.38, suggesting a potential downside of 18.73%. Zeltiq Aesthetics has a consensus target price of $56.25, suggesting a potential upside of Infinity. Given Zeltiq Aesthetics’ stronger consensus rating and higher possible upside, analysts clearly believe Zeltiq Aesthetics is more favorable than Abaxis.
Valuation and Earnings
This table compares Abaxis and Zeltiq Aesthetics’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Abaxis has higher revenue and earnings than Zeltiq Aesthetics. Zeltiq Aesthetics is trading at a lower price-to-earnings ratio than Abaxis, indicating that it is currently the more affordable of the two stocks.
Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc. is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system. CoolSculpting is a non-invasive fat reduction procedure. CoolSculpting utilizes its controlled cooling technology to selectively reduce stubborn fat bulges. The CoolSculpting system includes CoolSculpting control unit and CoolSculpting applicators. The CoolSculpting Applicator delivers vacuum suction and cooling to the fat bulge being treated.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.